Sterling Capital Management LLC Has $1.69 Million Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Sterling Capital Management LLC boosted its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 12.9% in the fourth quarter, HoldingsChannel reports. The firm owned 120,795 shares of the company’s stock after acquiring an additional 13,828 shares during the period. Sterling Capital Management LLC’s holdings in SI-BONE were worth $1,694,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SIBN. FMR LLC raised its holdings in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock valued at $33,000 after buying an additional 1,198 shares during the last quarter. Janus Henderson Group PLC increased its position in SI-BONE by 90.4% in the 3rd quarter. Janus Henderson Group PLC now owns 22,582 shares of the company’s stock valued at $316,000 after acquiring an additional 10,721 shares in the last quarter. State Street Corp lifted its position in shares of SI-BONE by 5.1% during the third quarter. State Street Corp now owns 1,081,871 shares of the company’s stock worth $15,125,000 after purchasing an additional 52,972 shares in the last quarter. Jane Street Group LLC grew its stake in shares of SI-BONE by 29.0% during the third quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after purchasing an additional 17,410 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of SI-BONE in the third quarter valued at approximately $448,000. Institutional investors own 98.11% of the company’s stock.

Insider Transactions at SI-BONE

In related news, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares of the company’s stock, valued at approximately $3,462,574.92. This represents a 1.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anthony J. Recupero sold 3,311 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now owns 284,555 shares in the company, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,776 shares of company stock valued at $96,644 over the last three months. 3.90% of the stock is currently owned by corporate insiders.

SI-BONE Trading Down 0.1 %

NASDAQ SIBN opened at $13.36 on Tuesday. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The stock has a 50-day simple moving average of $15.55 and a 200 day simple moving average of $14.64. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $567.17 million, a PE ratio of -14.52 and a beta of 1.02.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The company had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. Research analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, February 25th. Truist Financial reiterated a “buy” rating and issued a $22.00 price target (up previously from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Finally, Needham & Company LLC boosted their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE has a consensus rating of “Buy” and a consensus price target of $24.40.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.